Valuation: Tyra Biosciences, Inc.

Market Cap 1.75B 1.51B 1.43B 1.3B 2.43B 168B 2.45B 17.09B 6.58B 85.04B 6.57B 6.42B 271B P/E 2026 *
-9.5x
P/E 2027 * -8.84x
Enterprise Value 1.26B 1.09B 1.03B 933M 1.75B 121B 1.76B 12.29B 4.73B 61.18B 4.72B 4.62B 195B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Tyra Biosciences, Inc.

1 day+1.44%
1 week-4.86%
Current month+1.60%
1 month+0.55%
3 months-10.93%
6 months-29.79%
Current year-3.27%
1 week 21.27
Extreme 21.2744
26.36
1 month 18.66
Extreme 18.66
29.56
Current year 18.66
Extreme 18.66
40.65
1 year 12.12
Extreme 12.115
40.65
3 years 6.42
Extreme 6.42
40.65
5 years 4.93
Extreme 4.93
40.65
10 years 4.93
Extreme 4.93
40.65
Manager TitleAgeSince
Chief Operating Officer 51 31/10/2018
Chief Executive Officer 46 31/10/2018
Director of Finance/CFO 69 31/12/2022
Director TitleAgeSince
Chairman 58 28/02/2019
Director/Board Member 46 01/08/2018
Director/Board Member 40 31/12/2019
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Buy

Director

972 0.0016%
28/05/26 Free

Director

13,160 0.0221%
28/05/26 Free

Director

13,160 0.0221%
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%-4.86%+106.58%+72.88% 1.75B
-1.38%+0.20%+46.42%+96.33% 69.18B
-1.04%-0.81%+34.61%+75.16% 62B
-4.29%-3.98%-16.22%+350.66% 26.19B
+2.09%+2.89%+29.64%+15.25% 25.75B
-2.20%-2.00%-1.22%-14.48% 24.29B
+1.61%-0.69%+20.85%-19.42% 19.84B
+1.26%-14.23%+170.04%+298.75% 15.65B
-5.54%+0.69%-8.13%+830.48% 13.88B
-0.17%-4.03%-9.67%+456.14% 14.09B
Average -0.82%-2.46%+37.29%+216.18% 27.26B
Weighted average by Cap. -1.09%-1.34%+31.84%+157.44%

Financials

2026 *2027 *
Net sales - -
Net income -178M -154M -146M -132M -247M -17.04B -249M -1.74B -668M -8.64B -667M -653M -27.56B -211M -183M -173M -157M -294M -20.27B -296M -2.07B -795M -10.28B -794M -776M -32.78B
Net Debt -491M -425M -402M -364M -683M -47.06B -688M -4.8B -1.84B -23.86B -1.84B -1.8B -76.1B -323M -280M -264M -239M -449M -30.97B -453M -3.16B -1.21B -15.71B -1.21B -1.19B -50.09B
Logo Tyra Biosciences, Inc.
Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision medicines that target opportunities in FGFR biology. Its in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help it design and predict which candidates may demonstrate highest potency, selectivity and tolerability in clinic. Its expertise in FGFR biology has created a pipeline with clinical-stage programs in targeted oncology and genetically defined conditions. Its lead precision medicine stemming from SNAP, oral dabogratinib, is a potential first-in-class selective FGFR3 inhibitor in development for LG-UTUC, IR NMIBC and ACH. It is also developing TYRA-430, an oral, investigational FGFR4/3-biased inhibitor for FGF19+/FGFR4-driven cancers, in SURF431 study (advanced hepatocellular carcinoma), and TYRA-200, an oral, investigational, FGFR1/2/3 inhibitor, in SURF201 study (metastatic intrahepatic cholangiocarcinoma).
Employees
87
Date Price Change Volume
15/09/26 US$25.43 +1.44% 1,142,331
14/09/26 US$25.07 +13.80% 2,066,103
11/09/26 US$22.03 -6.41% 1,548,636
10/09/26 US$23.54 +6.95% 2,477,607
09/09/26 US$22.01 -17.66% 6,069,061
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
25.43USD
Average target price
48.30USD
Spread / Average Target
+89.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TYRA Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!